Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Participating in the Disruption of Traditional Centralized Laboratory Testing
- Point-of-care-testing offers numerous benefits, including faster results, lower costs, improved monitoring and medication adherence, and more
- It is set to disrupt the clinical chemistry field, promoting a shift to a more decentralized testing approach
- Avricore is taking part in this disruption through its POCT platform, HealthTab, found at select community pharmacies
- HealthTab combines point-of-care analyzers that screen for over 20 biomarkers with a consumer-facing interface that displays results
Point-of-care testing (“POCT”), experts say, is set to disrupt the clinical chemistry field, with further development in this area facilitating expanded delivery of healthcare to resource-poor environments, providing better tools for monitoring chronic diseases, and allowing for routine health monitoring for health-conscious individuals (https://nnw.fm/B9w2Y).
This disruption is contributing to a gradual shift from the traditional, more centralized testing approach in laboratories to a more decentralized system anchored in mobile communications and miniaturized diagnostic instruments. And, as an Abbott article notes (https://nnw.fm/IvoAl), this has brought with it several benefits.
“POCT is more convenient compared with traditional laboratory testing and has been shown to increase patient satisfaction. As a monitoring or screening tool, it can be used to support health screenings in those at risk of cardiovascular disease (‘CVD’) and improve patient compliance with testing frequency. There is now overwhelming evidence that POCT can offer significant strengthening of diagnostic precision of clinicians in a wide variety of areas,” the article, published in the 19th issue of Health Europa Quarterly, reads.
The article further observes that “POCT contributes to faster results for physicians, greater flexibility for physicians and patients, lower costs, improved medication adherence, and reduced antibiotics prescribing.”
Thanks to the vision and efforts of Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF), a health diagnostics solutions provider, an ever-expanding population of consumers around Canada can now enjoy these benefits.
Avricore’s flagship offering, HealthTab(TM), pairs point-of-care analyzers – manufactured by partners such as the above-mentioned article’s author, Abbott – with a secure, cloud-based network to create a robust turnkey POCT platform that has a consumer-facing interface and is domiciled in community pharmacies.
The analyzers screen for more than 20 biomarkers associated with select chronic and infectious diseases and communicate them in real-time with patients and trained health care professionals. In a November 23 announcement, Avricore celebrated the signing of a distribution agreement with Abbott that expanded its platform’s capabilities to better support patients with vital information about their renal function (https://nnw.fm/zxHZS).
“Understanding renal function in patients at risk from or already living with chronic disease is critical,” said Avricore CEO Hector Bremner. “With i-STAT Alinity and its associated test for creatinine, healthcare professionals can obtain results in approximately two minutes to detect elevated levels of creatinine that are associated with abnormal renal function.”
The company has also made significant progress in taking its services closer to even more patients. Since signing a Master Agreement to pilot its HealthTab platform in select Shoppers Drug Mart pharmacies in Ontario earlier this year, Avricore has rolled out its platform in additional locations, with the most recent move being expansion into British Columbia.
Avricore is guided by the vision to create the world’s largest testing network in community pharmacies. It seeks to make actionable health insights more accessible for everyone, including researchers and drug makers seeking de-identified patient data for their clinical studies.
For more information, visit the company’s website at www.AvricoreHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://nnw.fm/AVCRF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Point-of-care-testing offers numerous benefits, including faster results, lower costs, improved monitoring and medication adherence, and more
- It is set to disrupt the clinical chemistry field, promoting a shift to a more decentralized testing approach
- Avricore is taking part in this disruption through its POCT platform, HealthTab, found at select community pharmacies
- HealthTab combines point-of-care analyzers that screen for over 20 biomarkers with a consumer-facing interface that displays results
Point-of-care testing (“POCT”), experts say, is set to disrupt the clinical chemistry field, with further development in this area facilitating expanded delivery of healthcare to resource-poor environments, providing better tools for monitoring chronic diseases, and allowing for routine health monitoring for health-conscious individuals (https://nnw.fm/B9w2Y).
This disruption is contributing to a gradual shift from the traditional, more centralized testing approach in laboratories to a more decentralized system anchored in mobile communications and miniaturized diagnostic instruments. And, as an Abbott article notes (https://nnw.fm/IvoAl), this has brought with it several benefits.
“POCT is more convenient compared with traditional laboratory testing and has been shown to increase patient satisfaction. As a monitoring or screening tool, it can be used to support health screenings in those at risk of cardiovascular disease (‘CVD’) and improve patient compliance with testing frequency. There is now overwhelming evidence that POCT can offer significant strengthening of diagnostic precision of clinicians in a wide variety of areas,” the article, published in the 19th issue of Health Europa Quarterly, reads.
The article further observes that “POCT contributes to faster results for physicians, greater flexibility for physicians and patients, lower costs, improved medication adherence, and reduced antibiotics prescribing.”
Thanks to the vision and efforts of Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF), a health diagnostics solutions provider, an ever-expanding population of consumers around Canada can now enjoy these benefits.
Avricore’s flagship offering, HealthTab(TM), pairs point-of-care analyzers – manufactured by partners such as the above-mentioned article’s author, Abbott – with a secure, cloud-based network to create a robust turnkey POCT platform that has a consumer-facing interface and is domiciled in community pharmacies.
The analyzers screen for more than 20 biomarkers associated with select chronic and infectious diseases and communicate them in real-time with patients and trained health care professionals. In a November 23 announcement, Avricore celebrated the signing of a distribution agreement with Abbott that expanded its platform’s capabilities to better support patients with vital information about their renal function (https://nnw.fm/zxHZS).
“Understanding renal function in patients at risk from or already living with chronic disease is critical,” said Avricore CEO Hector Bremner. “With i-STAT Alinity and its associated test for creatinine, healthcare professionals can obtain results in approximately two minutes to detect elevated levels of creatinine that are associated with abnormal renal function.”
The company has also made significant progress in taking its services closer to even more patients. Since signing a Master Agreement to pilot its HealthTab platform in select Shoppers Drug Mart pharmacies in Ontario earlier this year, Avricore has rolled out its platform in additional locations, with the most recent move being expansion into British Columbia.
Avricore is guided by the vision to create the world’s largest testing network in community pharmacies. It seeks to make actionable health insights more accessible for everyone, including researchers and drug makers seeking de-identified patient data for their clinical studies.
For more information, visit the company’s website at www.AvricoreHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://nnw.fm/AVCRF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
